Asthma Therapeutics in Asia-Pacific Industrial and Market studiess to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Industrial and Market studies in Spite of Affordability Concerns
"Asthma
Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and
Launch of Late-Stage Biologics will Drive the Market in Spite of
Affordability Concerns"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Asthma
is a common chronic inflammatory disease of the airways,
characterized by recurrent attacks of breathlessness and wheezing,
which vary in frequency and severity from patient to patient. The
exact causes of asthma are currently unknown, and may be the result
of a combination of factors, although two major factors thought to be
involved are environmental exposure and host factors, particularly
genes.
Asthma
treatment can be classed as either a long-term control medication,
aimed at controlling persistent asthma, or a quick-relief medication,
for the relief of exacerbations and acute symptoms. Long-term control
medication includes Inhaled Corticosteroids (ICS), immunomodulators,
leukotriene modifiers, cromolyn sodium, nedocromil and
methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists
(LABAs) can be used in combination with ICSs – but not as
monotherapies – for moderate or severe persistent asthma.
Currently, only one biologic – Xolair (omalizumab) – is approved
as an add-on therapy for the treatment of allergic asthma in the
Asia-Pacific region. Nevertheless, significant unmet need
remains for the treatment of severe eosinophilic asthma.
Scope
The current asthma market in the Asia-Pacific
region contains novel products, including Xolair, a recombinant
humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA
combination therapy; Relvar/Breo, an ICS-LABA combination therapy,
and Spiriva, a LAMA.
- What are the competitive advantages of the existing novel drugs?
With over 274 active pipeline molecules, most of
the late-stage investigational drug candidates are being evaluated,
with improved dosing regimens and administration routes in comparison
to currently marketed products.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?
Analysis of clinical trials since 2006 has
identified that the failure rates of asthma molecules were highest in
Phase III (46%), with the overall attrition rate for asthma in
development being 78%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Reasons
to buy
This report will enable you to -
- Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
Comments
Post a Comment